So far as I know, zero. Number of patients is one so far as I know, and a Stanford patient, and the highest SD I ever heard of in a medical study - but that it entirely missing the point unless you are curious about what that marker is. Get in line, I don't think its published yet though I could be wrong.I would like to know what study you believe has a cohort with patients greater than N=1 that has a 16 standard deviation from normal measurable marker.
There are so many markers in us that are abnormal, that you might argue its not ME, or its not CFS, or some other similar disease, but its still a finding in one of us. At the research chemistry level it very much looks like an ME patient has way over 2000 things wrong with them but this is an inference. So the diagnosis might be wrong, or misleading, or cover many different diseases when its finally figured out, but my point is there are still thousands of things wrong. Even if a single patient has specific abnormalities, it fits my point. What we cannot do from that is extrapolate to findings in other patients, as the number of patients is too small. This applies to just about all of our studies though. Too small, on too low a budget, and with too many limitations on patient selection. Even repeat CPET only shows a problem in about 86% of us.
We also have the big issue that this is over a great many studies, so the cohort is different in most of them. Because all these tests were not done on one single cohort in a specific time frame, we cannot be sure how many will cluster, just as we cannot be sure a single cohort is typical. We also cannot be sure that every single finding is accurate and not an error. However with what is possibly way over 3000 findings now, many found in study after study, its entirely wrong to say nothing is wrong with us, or patients like us. There is only nothing wrong when you run tests for other diseases, or a limited range of exploratory tests, or maybe a rare individual who indeed has nothing wrong who is an outlier.
We also cannot be sure of the importance of these findings. Many might be secondary issues, not important in the final analysis. Indeed I strongly suspect that one or more key findings have not even been made yet, and will give us the chance to explain so much more about the disease when we figure out secondary consequences of that finding.
What can be said is nothing is wrong that typifies ME with 100% reliability. So no diagnostic biomarker, yet.
Last edited: